Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

Phase 2 Unknown 55 enrolled University of Vermont Cancer and Leukemia Group B · collab

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to determine the incidence of pegfilgrastim-induced back and leg pain and to determine whether the antihistamine loratadine can prevent pegfilgrastim-induced back and leg pain.

Timeline

Start: 2011-05
Primary completion: 2013-06
Completion: 2013-06

Publications

Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer. 2016 Jul;24(7):3085-93. doi: 10.1007/s00520-016-3119-0. Epub 2016 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Loratadine	Small molecule	10 mg	Oral

Indications

No indication recorded.